The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership of Dr. Marty Makary.Dr. Marty Makary, the F.D.A. commissioner, has faced intense criticism as the agency undergoes top-level turnover in critical areas like drug approvals.
F.D.A. Turmoil Keeps Spotlight on Its Commissioner
Scritto il 19/12/2025